Introduction: Traditional cancer therapies like chemotherapy and radiotherapy frequently face challenges, such as systemic toxicity, the development of resistance, and poor tolerance among patients. Recently, there has been a growing interest in herbal bioactive compounds because of their wide-ranging anticancer properties and natural sources. Nonetheless, the clinical use of these compounds is restricted by their low solubility in water, limited bioavailability, and rapid metabolic clearance. Methods: This review comprehensively assesses studies from 2010 to 2023 that investigate nanoformulation strategies aimed at enhancing the delivery of herbal bioactive agents in cancer treatment. The selection of studies was based on their examination of important nanocarrier systems, such as polymeric nanoparticles, liposomes, and lipid-based delivery platforms. The focus was on advancements in pharmacokinetics, drug targeting, and therapeutic outcomes. Results: Research shows that nanoformulated herbal compounds show improved stability, solubility, and controlled release characteristics. Polymeric and lipid-based nanocarriers significantly enhance drug accumulation in tumor tissues, thereby improving antitumor effectiveness and reducing systemic side effects. Numerous studies also demonstrate increased cellular uptake and extended circulation times with nano-encapsulated phytochemicals. Discussion: Nanoformulation technologies have effectively tackled numerous pharmacological challenges linked to herbal therapeutics. However, while laboratory and preclinical outcomes are promising, obstacles like obtaining regulatory approval, scaling up production, and ensuring consistent quality control impede clinical application. Additionally, the variability in plantderived compounds requires standardization to ensure reproducibility and safety. Conclusion: Nanoformulations of herbal bioactive compounds mark a significant advance in cancer treatment, providing enhanced solubility, targeted delivery, and lower toxicity. Despite the progress made, additional research is required to refine these formulations, address manufacturing and regulatory challenges, and incorporate these strategies into personalized cancer therapy models.
Zafar et al. (Tue,) studied this question.